UA123537C2 - Спосіб лікування жирової хвороби печінки із застосуванням антагоністів глюкокортикоїдних та мінералокортикоїдних рецепторів - Google Patents

Спосіб лікування жирової хвороби печінки із застосуванням антагоністів глюкокортикоїдних та мінералокортикоїдних рецепторів Download PDF

Info

Publication number
UA123537C2
UA123537C2 UAA201704069A UAA201704069A UA123537C2 UA 123537 C2 UA123537 C2 UA 123537C2 UA A201704069 A UAA201704069 A UA A201704069A UA A201704069 A UAA201704069 A UA A201704069A UA 123537 C2 UA123537 C2 UA 123537C2
Authority
UA
Ukraine
Prior art keywords
compound
liver disease
receptor
liver
fatty liver
Prior art date
Application number
UAA201704069A
Other languages
English (en)
Ukrainian (uk)
Inventor
Джозеф К. БЕЛАНОФФ
Хейзл Хант
Хэйзл Хант
Онно С. Меєр
Онно С. Меер
ден Хьовел Йосе ван
Original Assignee
Корцепт Терап'Ютікс, Інк.
Корцепт Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Корцепт Терап'Ютікс, Інк., Корцепт Терапьютикс, Инк. filed Critical Корцепт Терап'Ютікс, Інк.
Publication of UA123537C2 publication Critical patent/UA123537C2/uk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UAA201704069A 2014-10-15 2015-10-14 Спосіб лікування жирової хвороби печінки із застосуванням антагоністів глюкокортикоїдних та мінералокортикоїдних рецепторів UA123537C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462064358P 2014-10-15 2014-10-15
US201462092041P 2014-12-15 2014-12-15
PCT/US2015/055487 WO2016061195A1 (en) 2014-10-15 2015-10-14 Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Publications (1)

Publication Number Publication Date
UA123537C2 true UA123537C2 (uk) 2021-04-21

Family

ID=55747256

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201704069A UA123537C2 (uk) 2014-10-15 2015-10-14 Спосіб лікування жирової хвороби печінки із застосуванням антагоністів глюкокортикоїдних та мінералокортикоїдних рецепторів

Country Status (22)

Country Link
US (5) US10238659B2 (cg-RX-API-DMAC7.html)
EP (2) EP3206692B1 (cg-RX-API-DMAC7.html)
JP (1) JP6761410B2 (cg-RX-API-DMAC7.html)
KR (1) KR102435956B1 (cg-RX-API-DMAC7.html)
CN (2) CN107106562B (cg-RX-API-DMAC7.html)
AU (1) AU2015333645B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017007860B1 (cg-RX-API-DMAC7.html)
CA (1) CA2964625C (cg-RX-API-DMAC7.html)
DK (1) DK3206692T3 (cg-RX-API-DMAC7.html)
ES (1) ES2978871T3 (cg-RX-API-DMAC7.html)
FI (1) FI3206692T3 (cg-RX-API-DMAC7.html)
IL (1) IL251729B (cg-RX-API-DMAC7.html)
MX (1) MX2017004943A (cg-RX-API-DMAC7.html)
NZ (1) NZ731060A (cg-RX-API-DMAC7.html)
PH (1) PH12017500710B1 (cg-RX-API-DMAC7.html)
PL (1) PL3206692T3 (cg-RX-API-DMAC7.html)
PT (1) PT3206692T (cg-RX-API-DMAC7.html)
RU (1) RU2718921C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201703024VA (cg-RX-API-DMAC7.html)
UA (1) UA123537C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016061195A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201702813B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3206692B1 (en) 2014-10-15 2024-04-03 Corcept Therapeutics Incorporated Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
WO2019236487A1 (en) * 2018-06-04 2019-12-12 Corcept Therapeutics Incorporated Pyrimidine cyclohexenyl glucocorticoid receptor modulators
KR20210153056A (ko) 2019-03-18 2021-12-16 리네트 케이. 니만 인슐린 감수성 개선 방법
PH12022553008A1 (en) 2020-05-06 2024-03-04 Corcept Therapeutics Inc Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators
MX2022013804A (es) 2020-05-06 2022-11-30 Corcept Therapeutics Inc Polimorfos de moduladores de los receptores de pirimidin-ciclohexil-glucocorticoides.
KR102481705B1 (ko) * 2020-08-04 2022-12-27 연세대학교 산학협력단 트리아졸 유도체를 유효성분으로 포함하는 간 섬유증의 예방 또는 치료용 조성물
EP4263508A4 (en) * 2020-12-21 2024-11-27 Corcept Therapeutics Incorporated Method of preparing pyrimidine cyclohexyl glucocorticoid receptor modulators
WO2022235647A1 (en) * 2021-05-05 2022-11-10 Corcept Therapeutics Incorporated Methods for reducing liver fat and for treating fatty liver disorders
WO2025174745A1 (en) * 2024-02-12 2025-08-21 Corcept Therapeutics Incorporated MIRICORILANT TREATMENT FOR FATTY LIVER DISEASES and its EFFECTS on LIVER FAT CONTENT, FATTY ACIDS, ACYLGLYCEROLS, and SECONDARY BILE ACIDS
WO2025255357A1 (en) * 2024-06-06 2025-12-11 Corcept Therapeutics Incorporated Methods for preparing and maintaining livers and portions thereof for liver transplantation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2153546A (en) 1936-07-29 1939-04-11 Universal Draft Gear Attachmen Hand brake actuating mechanism
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
GB0213745D0 (en) * 2002-06-14 2002-07-24 Univ Edinburgh Enzyme
JP2006508042A (ja) 2002-07-18 2006-03-09 ブリストル−マイヤーズ スクイブ カンパニー グルココルチコイド受容体の修飾物質および方法
EP1883624B1 (en) 2005-05-18 2010-04-07 Merck Sharp & Dohme Corp. D-homoandrosta-17-yl-carbamate derivatives as selective glucocorticoid receptor ligands
US8389472B2 (en) * 2005-08-19 2013-03-05 Amylin Pharmaceuticals, Llc Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
KR20080065617A (ko) * 2005-09-19 2008-07-14 존슨 앤드 존슨 파머슈티컬 리서치 앤드 디벨로프먼트 엘엘씨 글루코코티코이드 수용체 발현의 조절
GB0601092D0 (en) * 2006-01-19 2006-03-01 Daniolabs Ltd The Prevention Of Systemic Side-Effects Of Glucocorticoids
EP2032134B1 (en) 2006-05-09 2015-06-24 Genzyme Corporation Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
JP2010523667A (ja) * 2007-04-13 2010-07-15 シェーリング コーポレイション ピリミジンジオン誘導体およびその使用方法
WO2009155481A1 (en) 2008-06-20 2009-12-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
AU2010232670B2 (en) 2009-04-03 2015-07-09 F. Hoffmann-La Roche Ag Propane- I-sulfonic acid {3- [5- (4 -chloro-phenyl) -1H-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
CN103596431B (zh) 2011-03-18 2016-06-22 科赛普特治疗公司 嘧啶环己基糖皮质激素受体调节剂
EP3206692B1 (en) 2014-10-15 2024-04-03 Corcept Therapeutics Incorporated Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Also Published As

Publication number Publication date
AU2015333645A1 (en) 2017-05-04
RU2017114596A (ru) 2018-11-15
US12226417B2 (en) 2025-02-18
KR102435956B1 (ko) 2022-08-23
EP3206692B1 (en) 2024-04-03
CA2964625C (en) 2023-03-07
RU2718921C2 (ru) 2020-04-15
EP4353310A2 (en) 2024-04-17
FI3206692T3 (fi) 2024-05-06
BR112017007860A2 (pt) 2018-01-16
JP2017531013A (ja) 2017-10-19
SG11201703024VA (en) 2017-05-30
AU2015333645B2 (en) 2020-01-30
DK3206692T3 (da) 2024-04-29
EP4353310A3 (en) 2024-06-19
EP3206692A1 (en) 2017-08-23
CA2964625A1 (en) 2016-04-21
US20160106749A1 (en) 2016-04-21
PT3206692T (pt) 2024-04-30
JP6761410B2 (ja) 2020-09-23
CN111557942A (zh) 2020-08-21
ES2978871T3 (es) 2024-09-23
CN107106562A (zh) 2017-08-29
PL3206692T3 (pl) 2024-07-22
EP3206692A4 (en) 2018-05-30
MX2017004943A (es) 2017-07-19
RU2017114596A3 (cg-RX-API-DMAC7.html) 2019-05-08
BR112017007860B1 (pt) 2023-03-07
IL251729A0 (en) 2017-06-29
NZ731060A (en) 2023-07-28
WO2016061195A1 (en) 2016-04-21
CN111557942B (zh) 2023-10-03
US20190151318A1 (en) 2019-05-23
US20210085682A1 (en) 2021-03-25
PH12017500710B1 (en) 2024-01-17
PH12017500710A1 (en) 2017-10-09
US11590135B2 (en) 2023-02-28
CN107106562B (zh) 2020-08-18
KR20170066646A (ko) 2017-06-14
ZA201702813B (en) 2019-05-29
IL251729B (en) 2020-03-31
US10238659B2 (en) 2019-03-26
US10881660B2 (en) 2021-01-05
US20250221995A1 (en) 2025-07-10
US20230218621A1 (en) 2023-07-13

Similar Documents

Publication Publication Date Title
UA123537C2 (uk) Спосіб лікування жирової хвороби печінки із застосуванням антагоністів глюкокортикоїдних та мінералокортикоїдних рецепторів
US12263169B2 (en) Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators
UA127409C2 (uk) Модулятори глюкокортикоїдного рецептора для лікування раку шийки матки
KR20190040511A (ko) 췌장암을 치료하기 위한 글루코코르티코이드 수용체 조정제
Suzukawa et al. Leptin enhances ICAM-1 expression, induces migration and cytokine synthesis, and prolongs survival of human airway epithelial cells
Lopez‐Charcas et al. Blockade of CaV3 calcium channels and induction of G0/G1 cell cycle arrest in colon cancer cells by gossypol
Zhou et al. Treatment of experimental non-alcoholic steatohepatitis by targeting α7 nicotinic acetylcholine receptor-mediated inflammatory responses in mice
CA2619480A1 (en) Method of using potassium channel inhibiting compounds
HK40102771A (en) Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
HK1240087A1 (en) Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
HK1240087B (zh) 使用糖皮質激素和鹽皮質激素受體拮抗劑的脂肪肝疾病治療
HK40027249A (en) Treatment of neuroepithelial tumors using selective glucocorticoid receptor modulators
HK40027249B (en) Treatment of neuroepithelial tumors using selective glucocorticoid receptor modulators